- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03137589
Telemedical, Intersectoral Network as New Digital Health Structure to Measurably Improve the Local Health Care (TELnet@NRW)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In future time the number of old people will significantly increase in Germany because of the demographic change taking place. The health care of the large number of old people will probably lead to a lack of physicians and an inefficient health care system. One strategy to tackle the problem could be telemedicine. Telemedicine makes it possible to provide know-ledge from experts to local hospitals and practices which otherwise need to send patients with serious and complex diseases to specialized trans-regional health centers. In this multicenter, prospective, non-interventional study hospitals and practices in NRW are supplied via a telematics platform with expert know-ledge from the university hospitals RWTH Aachen and Münster. The communication occurs via highly encrypted audio/video conference systems and a certified data exchange platform "Fallakte+".
In total 40.000 outpatient and stationary patients should be treated with telemedical support. Registered doctors will be involved in already existing practice networks to evaluate the potential for transfer and to ensure the sharing of know-ledge beyond the borders of individual sectors. The aim of the study is to improve the treatment quality of regional hospitals and practices and to increase the efficiency of the care of relevant patient cohort in the field of infectiology and intensive care with the main focus sepsis as those patient groups especially often require professional expertise for a successful therapy.
In the beginning of the study participating hospitals and practices are randomly distributed into four clusters (cluster randomization). The different clusters all start with the control phase but enter into the intervention phase at different times (stepped-wedge design). During the control phase data of patients with infection and intensive care patients routinely treated without the support of telemedicine are documented and the patients are asked to complete a questionnaire regarding health-related quality of life (SF36) directly after treatment and at two time points in the follow-up. The collected data will be later compared to data obtained in the same way from patients treated with telemedical support and evaluated regarding differences in the quality of treatment, therapeutic process and the satisfaction of the patients with telemedicine.
If the study shows that the treatment quality and therapeutic process of patients with infectious diseases or need for intensive care is improved by telemedicine, the telematics platform can be expanded and used by other specialized fields and users in future time.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Münster, Germany
- University Hospital Münster
-
-
NRW
-
Aachen, NRW, Germany, 52074
- University Hospital RWTH Aachen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- majority
- written informed consent
- infectiological and/or intensive care treatment
Exclusion Criteria:
- minority
- absence of written informed consent in the case of non-acute life-threatening disease
- persons who have a dependency or employment relationship with the sponsor or investigator
- persons who are sheltered in an institution upon court or administrative order
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Patients of this group are routinely treated without telemedical support.
|
|
Active Comparator: Telemedical support
Patients of this group are routinely treated with telemedical support.
|
Participating sites will be advised by telemedicine support.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement of treatment quality
Time Frame: through study completion, an average of 30 days up to a maximum of 1 year
|
The level of implementation of the 10 recommendations of the German Society of Infectious Diseases (Deutsche Gesellschaft für Infektiologie, DGI) within the framework of the Initiative "Decide wisely" ("Klug entscheiden").
|
through study completion, an average of 30 days up to a maximum of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of sepsis diagnosis
Time Frame: through study completion, an average of 30 days up to a maximum of 1 year
|
Rate of sepsis diagnosis
|
through study completion, an average of 30 days up to a maximum of 1 year
|
Rate of ARDS Diagnosis
Time Frame: through study completion, an average of 30 days up to a maximum of 1 year
|
Rate of ARDS Diagnosis
|
through study completion, an average of 30 days up to a maximum of 1 year
|
Sepsis therapy in compliance with guidelines
Time Frame: through study completion, an average of 30 days up to a maximum of 1 year
|
Sepsis therapy in compliance with guidelines through for instance timely administration of antibiotics within 3 h and reduction of sepsis mortality.
|
through study completion, an average of 30 days up to a maximum of 1 year
|
Rate of ARDS therapy according to guidelines
Time Frame: through study completion, an average of 30 days up to a maximum of 1 year
|
Measured against the evident ventilation targets, Ventilation with low ventilation volumes and low peak pressures: with controlled ventilation: Breath volume of 6 ml/kg calculated Body ideal weight, PEEP setting in proportion with the necessary FiO2, plateau pressure < 30 cm H2O |
through study completion, an average of 30 days up to a maximum of 1 year
|
Rate of inadequate antibiotic therapies
Time Frame: through study completion, an average of 30 days up to a maximum of 1 year
|
Measured by the Percentage of postoperatively continued perioperative Antibiotic prophylaxis
|
through study completion, an average of 30 days up to a maximum of 1 year
|
Rate of patients with dialysis
Time Frame: At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
|
Rate of patients with dialysis requiring Kidney insufficiency in discharge from the Intensive care
|
At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
|
Rate of transfer transport
Time Frame: At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
|
Rate of transfer transport
|
At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
|
Health-related quality of life (SF36-Questionnaire)
Time Frame: At discharge from Intensive Care Unit (through study completion; an average of 30 days up to a maximum of 1 year), through study completion, an average of 12 months and 24 months after discharge of ICU
|
Clinical studies 36-item Medical Outcomes Study Short-Form General Health Survey An instrument used to assess multidimensional health-related QOL, which measures 8 health related parameters: physical function, social function, physical role, emotional role, mental health, energy, pain, general health perceptions; each parameter is scored from 0 to 100 Managed care 36-Item Short-Form Functional and Perceived Health Status Survey A questionnaire which measures health status; the SF-36 also includes a list of 18 self-reported chronic conditions
|
At discharge from Intensive Care Unit (through study completion; an average of 30 days up to a maximum of 1 year), through study completion, an average of 12 months and 24 months after discharge of ICU
|
Rate of non-diagnosed sepsis
Time Frame: through study completion, an average of 30 days up to a maximum of 1 year
|
Defined as no filled out sepsis bundle despite presence of sepsis symptoms
|
through study completion, an average of 30 days up to a maximum of 1 year
|
Sepsis mortality rate
Time Frame: through study completion, an average of 30 days up to a maximum of 1 year
|
Sepsis mortality rate
|
through study completion, an average of 30 days up to a maximum of 1 year
|
Hospital mortality rate
Time Frame: through study completion, an average of 30 days up to a maximum of 1 year
|
Hospital mortality rate
|
through study completion, an average of 30 days up to a maximum of 1 year
|
Length of stay in intensive care unit
Time Frame: At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
|
Length of stay in intensive care unit measured in hours
|
At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
|
Hospital stay
Time Frame: At discharge from Hospital; after an average of 30 days up to a maximum of 1 year
|
Hospital stay measured in days
|
At discharge from Hospital; after an average of 30 days up to a maximum of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gernot Marx, Univ.-Prof. Dr. med., Clinic for Operative Intensive Care and Intermediate Care, University Hospital RWTH Aachen
Publications and helpful links
General Publications
- Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007 Apr;33(4):606-18. doi: 10.1007/s00134-006-0517-7. Epub 2007 Feb 24.
- Reinhart K, Brunkhorst FM, Bone HG, Bardutzky J, Dempfle CE, Forst H, Gastmeier P, Gerlach H, Grundling M, John S, Kern W, Kreymann G, Kruger W, Kujath P, Marggraf G, Martin J, Mayer K, Meier-Hellmann A, Oppert M, Putensen C, Quintel M, Ragaller M, Rossaint R, Seifert H, Spies C, Stuber F, Weiler N, Weimann A, Werdan K, Welte T; German Sepsis Society; German Interdisciplinary Association of Intensive Care and Emergency Medicine. Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinare Vereinigung fur Intensiv- und Notfallmedizin (DIVI)). Ger Med Sci. 2010 Jun 28;8:Doc14. doi: 10.3205/000103.
- Laxminarayan R, Bhutta Z, Duse A, Jenkins P, O'Brien T, Okeke IN, Pablo-Mendez A, Klugman KP. Drug Resistance. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2006. Chapter 55. Available from http://www.ncbi.nlm.nih.gov/books/NBK11774/
- Marx G, Greiner W, Juhra C, Elkenkamp S, Gensorowsky D, Lemmen S, Englbrecht J, Dohmen S, Gottschalk A, Haverkamp M, Hempen A, Flugel-Bleienheuft C, Bause D, Schulze-Steinen H, Rademacher S, Kistermann J, Hoch S, Beckmann HJ, Lanckohr C, Lowitsch V, Peine A, Juzek-Kuepper F, Benstoem C, Sperling K, Deisz R. An Innovative Telemedical Network to Improve Infectious Disease Management in Critically Ill Patients and Outpatients (TELnet@NRW): Stepped-Wedge Cluster Randomized Controlled Trial. J Med Internet Res. 2022 Mar 2;24(3):e34098. doi: 10.2196/34098.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 16-162
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection
-
Radboud University Medical CenterSint MaartenskliniekActive, not recruitingSurgical Site Infection | Joint Infection | Infection, Surgical Site | Infection Prosthesis Hip and Knee | Infection, Prosthesis Related | Infection ProNetherlands
-
West Virginia UniversityEnrolling by invitationSkin and Soft Tissue Infection | Gastrointestinal Infection | Pulmonary Infection | Bone and Joint Infection | Endovascular Infection | Genitourinary InfectionUnited States
-
Ondine Biomedical Inc.CompletedSurgical Site Infection | Nosocomial Infection | Healthcare Associated InfectionUnited States
-
Gundersen Lutheran Medical FoundationGundersen Lutheran Health SystemCompletedSurgical Site Infection | Superficial Surgical Site Infection | Deep Surgical Site Infection | Organ/Space Surgical Site InfectionUnited States
-
Croydon Health Services NHS TrustCompletedSurgical Site Infection | Wound Infection | Cesarean Section; Infection | Perineal InfectionUnited Kingdom
-
Cairo UniversityRecruitingPostoperative Infection | Cesarean Section Complications | Vaginal InfectionEgypt
-
Vastra Gotaland RegionGöteborg UniversityRecruitingProsthetic Joint Infection | Hip Prosthesis Infection | Prosthetic Infection | Knee Prosthesis InfectionSweden
-
University of ZurichRecruitingProsthetic Joint Infection | Surgical Site Infection | Prosthesis and Implants | Postoperative Wound Infection Deep Incisional Surgical SiteSwitzerland
-
Ondine Biomedical Inc.CompletedNosocomial Infection | Surgical Site Infections | Healthcare Associated InfectionsUnited States
-
Leiden University Medical CenterRadboud University Medical Center; University Medical Center Groningen; Erasmus... and other collaboratorsRecruitingProsthetic-joint Infection | Infection Hip | Infection; Knee, JointNetherlands
Clinical Trials on Telemedical support
-
RWTH Aachen UniversityCompletedAcute Coronary SyndromeGermany
-
RWTH Aachen UniversityOptimal@NRW Research GroupRecruiting
-
RWTH Aachen UniversityOptimal@NRW Research GroupCompleted
-
West German Center of Diabetes and HealthCompleted
-
RWTH Aachen UniversityCompletedHypertensive Urgency | Hypertensive EmergencyGermany
-
Odense University HospitalUniversity of Southern Denmark; Danish Lung Association; Region of Southern Denmark and other collaboratorsWithdrawnPulmonary Disease, Chronic Obstructive
-
Erling Bjerregaard PedersenCompleted
-
University Hospital, Basel, SwitzerlandInnosuisse - Swiss Innovation AgencyRecruiting
-
University of Erlangen-Nürnberg Medical SchoolCharite University, Berlin, Germany; University Hospital, EssenRecruiting
-
University Hospital, Basel, Switzerlandpropatient ForschungsstiftungRecruiting